Market Place
Sourcing Support
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
25 Nov 2024 //
GLOBENEWSWIRE
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
23 Oct 2024 //
GLOBENEWSWIRE
BetterLife Announces Fully Subscribed Private Placement Financing
29 Aug 2024 //
GLOBENEWSWIRE
BetterLife Highlights Non-Hallucinogenic LSD Derivative For Mood Disorders
27 Aug 2024 //
GLOBENEWSWIRE
Amendment of Disclosures in Past Management Information Circulars
16 Jul 2024 //
GLOBENEWSWIRE
BetterLife Announces Closing of a Private Placement
02 Jul 2024 //
GLOBENEWSWIRE
BetterLife To Present BETR-001 Preclinical Data at FENS 2024
26 Jun 2024 //
GLOBENEWSWIRE
BetterLife Obtains Excellent BETR-001 Animal Cardiopulmonary Safety Data
14 May 2024 //
GLOBENEWSWIRE
BetterLife Announces Intent to Complete Private Placement of Units
03 May 2024 //
GLOBENEWSWIRE
BetterLife Advances BETR-001 IND-enabling Studies
01 May 2024 //
GLOBENEWSWIRE
BetterLife To Present At Bloom Burton Healthcare Investor Conf 2024
11 Apr 2024 //
GLOBENEWSWIRE
BetterLife Announces Closing of $1.168M to Advance IND-enabling Studies
03 Apr 2024 //
GLOBENEWSWIRE
BetterLifes 2-Bromo-LSD for Treatment of Depression
04 Mar 2024 //
GLOBENEWSWIRE
BetterLife Announces Closing of Convertible Debentures For BETR-001
02 Jan 2024 //
GLOBENEWSWIRE
BetterLife Announces Extension of Warrants
30 Nov 2023 //
GLOBENEWSWIRE
Patent & Trademark Office Publishes BetterLife™s Patent for BETR-001
15 Nov 2023 //
GLOBENEWSWIRE
BetterLife Pharma to Host Investors Update Call on September 18, 2023
14 Sep 2023 //
GLOBENEWSWIRE
BetterLife Obtains Animal Safety Data for Repeated Oral Dosing of BETR-001
12 Sep 2023 //
GLOBENEWSWIRE
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery
05 Sep 2023 //
GLOBENEWSWIRE
BetterLife Highlights American College of Physicians’ Updated Guidelines
13 Jul 2023 //
GLOBENEWSWIRE
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
27 Jun 2023 //
GLOBENEWSWIRE
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting
22 Jun 2023 //
GLOBENEWSWIRE
BetterLife Continues Progress on BETR-001 IND-Enabling Studies
08 Jun 2023 //
GLOBENEWSWIRE
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting
25 Apr 2023 //
GLOBENEWSWIRE
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare
20 Apr 2023 //
GLOBENEWSWIRE
BetterLife`s Non-hallucinogenic LSD For Treating Mood Disorders Highlighted
29 Mar 2023 //
GLOBENEWSWIRE
Promise of BetterLife`s Non-hallucinogenic LSD For Treating Mood Disorders
22 Mar 2023 //
GLOBENEWSWIRE
BetterLife Closes $1,857,143 of Private Placement
14 Mar 2023 //
GLOBENEWSWIRE
BetterLife Files Amended and Restated Offering Document for Offering of Units
10 Mar 2023 //
GLOBENEWSWIRE
Betterlife Publishes Results from Study Titled A Non-Hallucinogenic LSD Analog
09 Mar 2023 //
GLOBENEWSWIRE
BetterLife Announces Offering of Units
07 Mar 2023 //
GLOBENEWSWIRE
BetterLife Announces Engagement of Bloom Burton Securities Inc.
26 Jan 2023 //
GLOBENEWSWIRE
BetterLife Announces Closing of Private Placement
07 Dec 2022 //
GLOBENEWSWIRE
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting
02 Dec 2022 //
GLOBENEWSWIRE
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
27 Sep 2022 //
GLOBENEWSWIRE
BetterLife and Collaborators to Submit Key Joint Research Publication
07 Sep 2022 //
GLOBENEWSWIRE
BetterLife Lead Drug Promotes Neural Plasticity with Nootropic Effects
24 Aug 2022 //
GLOBENEWSWIRE
BetterLife To Participate at the H.C. Wainwright Conference
23 Jun 2022 //
GLOBENEWSWIRE
BetterLife To Present BETR-001 Preclinical Data at the Upcoming FENS Forum
21 Jun 2022 //
GLOBENEWSWIRE
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian
21 Apr 2022 //
GLOBENEWSWIRE
BetterLife Obtains In Vivo PK Data for BETR-001 Confirming Bioavailability
16 Mar 2022 //
GLOBENEWSWIRE
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity
15 Feb 2022 //
GLOBENEWSWIRE
BetterLife Obtains Positive Data for BETR-001
18 Jan 2022 //
GLOBENEWSWIRE
BetterLife’s Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains
22 Dec 2021 //
GLOBENEWSWIRE
BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression
09 Dec 2021 //
GLOBENEWSWIRE
BetterLife Successfully Completes Phase 1 and Initiates Phase 2
29 Nov 2021 //
GLOBENEWSWIRE
BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
16 Nov 2021 //
PRESS RELEASE
BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
05 Nov 2021 //
PRESS RELEASE
BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Studies
29 Sep 2021 //
GLOBENEWSWIRE
BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
22 Sep 2021 //
GLOBENEWSWIRE
BetterLife to Present at the Emerging Growth Conference on September 15, 2021
13 Sep 2021 //
GLOBENEWSWIRE
BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A
09 Sep 2021 //
PRESS RELEASE
BetterLife Initiates Preclinical Study of AP-003 in Delta Variant of SARS-CoV-2
25 Aug 2021 //
GLOBENEWSWIRE
BetterLife to commence trial of inhaled drug for Covid-19 in Chile
28 Jul 2021 //
CLINICAL TRIAL ARENA
BetterLife Research Team Mitacs Accelerate Study Therapeutic Effect of TD-010
22 Jul 2021 //
GLOBENEWSWIRE
BetterLife Research Team Mitacs Accelerate Study Therapeutic Effect of TD-010
22 Jul 2021 //
GLOBENEWSWIRE
Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b)
15 Jul 2021 //
GLOBE NEWSWIRE
BetterLife Announces Exercise of Over-Allotment Option in Public Offering
25 Jun 2021 //
GLOBENEWSWIRE
